Purified COX isoform inhibition
Biochemical assay · Purified hematin-reconstituted ovine COX-1, murine COX-2 and human COX-2 [1]
Indomethacin inhibited all three enzymes, with lower IC50 for ovine COX-1 than either COX-2 preparation. Values average at least two independent determinations.
| Endpoint | Reported result | Reference |
|---|---|---|
| Arachidonic acid conversion by ovine COX-1 | IC50 27 nM | [1] |
| Arachidonic acid conversion by murine COX-2 | IC50 127 nM | [1] |
| Arachidonic acid conversion by human COX-2 | IC50 180 nM | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Varying indomethacin concentrations; 50 μM [1-14C]arachidonic acid substrate
- Exposure duration
- 17 min preincubation at 25 °C, then 3 min at 37 °C; substrate reaction 30 s at 37 °C
- Method
- Time-dependent COX inhibition screening assay; 100 mM Tris-HCl with 500 μM phenol
- Vehicle
- Dimethyl sulfoxide
- Reported limits
- Figure 3 caption does not define an error-bar statistic. No lot-specific indomethacin characterization supplied.
Methods and source locations
Compound reported in the paper: Indomethacin; Compound label in the paper: INDO
Compound-level research evidence; no Adooq lot or purity validation.
Figure 3A/caption and adjacent results; SI pp. 2–4
Arachidonic acid conversion by ovine COX-1: Radiolabeled substrate consumption by thin-layer chromatography — Figure 3A/caption; SI pp. 3–4, Enzymes and COX Inhibition Screening Assay
Arachidonic acid conversion by murine COX-2: Radiolabeled substrate consumption by thin-layer chromatography — Figure 3A/caption; SI pp. 3–4, Enzymes and COX Inhibition Screening Assay
Arachidonic acid conversion by human COX-2: Radiolabeled substrate consumption by thin-layer chromatography — Figure 3A/caption; SI pp. 3–4, Enzymes and COX Inhibition Screening Assay